Alseres Pharmaceuticals 10-K 10 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 15, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-K	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'
Entity Registrant Name	'ALSERES PHARMACEUTICALS INC /DE	'
Entity Central Index Key	'0000094784	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	30,635,720
Entity Public Float	$304,000	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$113,958	$16,528
Short-term investments	196,650	838,309
Restricted marketable securities	10,350	42,450
Prepaid expenses and other current assets	3,686	2,720
Total current assets	324,644	900,007
Property and equipment, net	'	1,186
Deferred charges	60,827	64,514
Total assets	385,471	965,707
Current liabilities:	'	'
Accounts payable and accrued expenses	1,055,738	2,278,398
Notes payable	'	6,410,000
Accrued interest	5,630	919,526
Other current liabilities	13,221	60,126
Advances from related party	500,000	325,000
Deferred revenue	73,731	73,730
Total current liabilities	1,648,320	10,066,780
Contingent royalty	0	16,000,000
Deferred revenue, net of current portion	1,142,816	1,216,547
Long term note payable	7,819,960	'
Other long-term liabilities	43,750	33,750
Total liabilities	10,654,846	27,317,077
Commitments and contingencies (Note 13)	'	'
Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at December 31, 2013 and 2012 (liquidation preference of $300,000 at December 31, 2013)	390,443	369,501
Stockholders' deficit:	'	'
Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at December 31, 2013 and 2012	'	'
Common stock, $.01 par value; 80,000,000 shares authorized at December 31, 2013 and 2012; 30,635,720 issued and outstanding at December 31, 2013 and 2012	306,357	306,357
Additional paid-in capital	188,662,248	171,975,520
Accumulated other comprehensive income (loss)	6,650	-309,204
Deficit accumulated during development stage	-199,635,073	-198,693,544
Total stockholders' deficit	-10,659,818	-26,720,871
Total liabilities and stockholders' deficit	$385,471	$965,707

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	30,635,720	30,635,720
Common stock, shares outstanding	30,635,720	30,635,720
Series F Preferred Stock [Member]	'	'
Convertible redeemable preferred stock, shares par value per share	$0.01	$0.01
Convertible redeemable preferred stock, shares designated	200,000	200,000
Convertible redeemable preferred stock, shares issued	12,000	12,000
Convertible redeemable preferred stock, shares outstanding	12,000	12,000
Preferred stock, shares liquidation preference	$300,000	'
Series A Preferred Stock [Member]	'	'
Preferred stock, shares authorized	25,000	25,000
Series D Preferred Stock [Member]	'	'
Preferred stock, shares authorized	500,000	500,000
Series E Preferred Stock [Member]	'	'
Preferred stock, shares authorized	800	800

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended		254 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement [Abstract]	'	'	'
Revenues	$473,730	$530,720	$1,904,450
Operating expenses:	'	'	'
General and administrative	1,419,792	1,665,605	71,902,285
Research and development	'	50,750	116,092,348
Sublicense and option fees	23,687	26,536	50,223
Purchased in-process research and development	'	'	12,146,544
Operating expenses before accrual reversal	1,443,479	1,742,891	200,191,400
Accrual reversal	-405,026	'	-966,221
Total operating expenses	1,038,453	1,742,891	199,225,179
Loss from operations	-564,723	-1,212,171	-197,320,729
Interest expense	-454,662	-434,551	-15,378,323
Investment income	819	341	7,706,164
Realized loss on sale of marketable securities	-263,154	'	-263,154
Other income (expense), net	340,191	905	-1,132,968
Gain on early extinguishment of debt	'	'	6,277,100
Forgiveness of debt	'	'	476,837
Net loss	-941,529	-1,645,476	-199,635,073
Preferred stock beneficial conversion feature	'	'	-8,062,712
Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders	'	'	-1,229,589
Net loss	-941,529	-1,645,476	-208,927,374
Other comprehensive income (loss)	'	'	'
Unrealized holding gain (loss) arising during the year	52,700	-277,837	-256,504
Less: reclassification adjustments for loss on sale included in net loss	-263,154	'	-263,154
Total other comprehensive income (loss)	315,854	-277,837	6,650
Comprehensive loss	($625,675)	($1,923,313)	($208,920,724)
Net loss per common share, basic and diluted	($0.03)	($0.06)	'
Weighted average common shares outstanding, basic and diluted	30,635,720	30,635,720	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' (Deficit) Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Deferred Compensation [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Deficit Accumulated During Development Stage [Member]
Beginning Balance at Oct. 16, 1992	'	'	'	'	'	'	'
Beginning Balance, Shares at Oct. 16, 1992	'	'	'	'	'	'	'
Issuance of common stock	48,725	'	3,040	45,685	'	'	'
Issuance of common stock, shares	'	'	304,009	'	'	'	'
Exercise of warrants and stock options	7,596,439	'	11,850	7,584,589	'	'	'
Exercise of warrants and stock options, shares	'	'	1,185,039	'	'	'	'
Issuance of common stock and warrants, net of issuance costs	56,458,546	'	115,168	56,343,378	'	'	'
Issuance of common stock and warrants, net of issuance costs, shares	'	'	11,516,790	'	'	'	'
Issuance of common stock and warrants upon Merger	14,603,948	'	7,239	14,596,709	'	'	'
Issuance of common stock and warrants upon Merger, shares	'	'	723,947	'	'	'	'
Conversion of convertible debentures	988,591	'	313	988,278	'	'	'
Conversion of convertible debentures, shares	'	'	31,321	'	'	'	'
Issuance of warrants related to debentures, net of issuance costs	3,632,632	'	'	3,632,632	'	'	'
Issuance of warrants related to preferred series C stock and BCF, net of issuance costs	3,736,789	'	'	3,736,789	'	'	'
Preferred stock, net of issuance costs	25,584,456	2,296,355	'	23,288,101	'	'	'
Preferred stock, net of issuance costs, shares	'	240,711	'	'	'	'	'
Conversion of Preferred Stock K and payment of interest, net of issuance costs	6,179,186	-1,491,474	15,538	7,655,122	'	'	'
Accretion of preferred stock	-4,327,679	'	'	-4,327,679	'	'	'
Conversion of Preferred Stock K and payment of interest, net of issuance costs, shares	'	-240,149.70	1,553,749	'	'	'	'
Conversion of debentures and payment of interest, net of issuance costs	4,847,420	'	3,171	4,844,249	'	'	'
Conversion of debentures and payment of interest, net of issuance costs, shares	'	'	317,083	'	'	'	'
Conversion of preferred stock and modification of warrants	'	-3,501,539	9,006	3,492,533	'	'	'
Conversion of preferred stock and modification of warrants, shares	'	-561.3	900,646	'	'	'	'
Preferred stock conversion inducement	-600,564	'	'	-600,564	'	'	'
Amortization of preferred stock Series E BCF	'	2,696,658	'	-2,696,658	'	'	'
Issuance of warrants related to Series E Stock, net of issuance costs	2,049,297	'	'	2,049,297	'	'	'
Issuance of common stock and cancellation of warrants	'	'	427	-427	'	'	'
Issuance of common stock and cancellation of warrants, shares	'	'	42,667	'	'	'	'
Dividend accrual preferred Series E	-573,597	'	'	-573,597	'	'	'
BCF on convertible notes payable	558,000	'	'	558,000	'	'	'
Deferred compensation- stock options and warrants	'	'	'	804,607	-804,607	'	'
Share-based compensation	4,274,806	'	'	3,470,199	804,607	'	'
Modification of options and warrants	1,804,694	'	'	1,804,694	'	'	'
Other	69,933	'	8	69,925	'	'	'
Other, shares	'	'	783	'	'	'	'
Net income (loss)	-143,503,529	'	'	'	'	'	-143,503,529
Ending Balance at Dec. 31, 2006	'	'	'	'	'	'	'
Exercise of warrants and stock options	145,705	'	2,022	143,683	'	'	'
Exercise of warrants and stock options, shares	'	'	202,183	'	'	'	'
Conversion of convertible debentures	10,000,000	'	40,000	9,960,000	'	'	'
Conversion of convertible debentures, shares	'	'	4,000,000	'	'	'	'
BCF on convertible notes payable	1,880,000	'	'	1,880,000	'	'	'
Share-based compensation	1,665,155	'	'	1,665,155	'	'	'
Modification of options and warrants	5,614	'	'	5,614	'	'	'
Net income (loss)	-19,548,348	'	'	'	'	'	-19,548,348
Net Unrealized gain (loss) on marketable securities	9,310	'	'	'	'	9,310	'
Ending Balance at Dec. 31, 2007	-22,414,471	'	207,782	140,420,314	'	9,310	-163,051,877
Ending Balance, shares at Dec. 31, 2007	'	'	20,778,217	'	'	'	'
Issuance of common stock	1,085,275	'	5,718	1,079,557	'	'	'
Issuance of common stock, shares	'	'	571,806	'	'	'	'
Exercise of warrants and stock options	2,541	'	11	2,530	'	'	'
Exercise of warrants and stock options, shares	'	'	1,100	'	'	'	'
Conversion of convertible debentures	120,000	'	480	119,520	'	'	'
Conversion of convertible debentures, shares	'	'	48,000	'	'	'	'
BCF on convertible notes payable	380,000	'	'	380,000	'	'	'
Share-based compensation	1,670,063	'	'	1,670,063	'	'	'
Net income (loss)	-20,847,459	'	'	'	'	'	-20,847,459
Net Unrealized gain (loss) on marketable securities	-9,310	'	'	'	'	-9,310	'
Ending Balance at Dec. 31, 2008	-40,013,361	'	213,991	143,671,984	'	'	-183,899,336
Ending Balance, shares at Dec. 31, 2008	'	'	21,399,123	'	'	'	'
Issuance of common stock	2,002,000	'	41,565	1,960,435	'	'	'
Issuance of common stock, shares	'	'	4,156,522	'	'	'	'
Accretion of convertible redeemable preferred stock	-194,107	'	'	-192,107	'	'	-2,000
Share-based compensation	1,473,083	'	'	1,473,083	'	'	'
Net income (loss)	-10,776,937	'	'	'	'	'	-10,776,937
Ending Balance at Dec. 31, 2009	-47,509,322	'	255,556	146,913,395	'	'	-194,678,273
Ending Balance, shares at Dec. 31, 2009	'	'	25,555,645	'	'	'	'
Issuance of common stock	0	'	15,000	-15,000	'	'	'
Issuance of common stock, shares	'	'	1,500,000	'	'	'	'
Accretion of preferred stock	-343,000	'	'	-343,000	'	'	'
Share-based compensation	61,722	'	'	61,722	'	'	'
Buyback of common stock	-8,100	'	-2,700	-5,400	'	'	'
Buyback of common stock, shares	'	'	-270,000	'	'	'	'
Net income (loss)	512,419	'	'	'	'	'	512,419
Ending Balance at Dec. 31, 2010	-47,286,281	'	267,856	146,611,717	'	'	-194,165,854
Ending Balance, shares at Dec. 31, 2010	'	'	26,785,645	'	'	'	'
Conversion of convertible debentures	7,172,412	'	28,690	7,143,722	'	'	'
Conversion of convertible debentures, shares	'	'	2,868,965	'	'	'	'
Accretion of preferred stock	486,663	'	'	486,663	'	'	'
Issuance of common stock-debt forgiveness	28,680	'	3,585	25,095	'	'	'
Issuance of common stock-debt forgiveness, shares	'	'	358,500	'	'	'	'
Share-based compensation	834	'	'	834	'	'	'
Buyback of common stock per share	-7,172	'	-28,690	21,518	'	'	'
Buyback of common stock per share, shares	'	'	-2,868,965	'	'	'	'
Buyback of common stock	-11,084	'	-11,084	'	'	'	'
Buyback of common stock, shares	'	'	-1,108,425	'	'	'	'
Forgiveness of accrued interest on convertible debt	6,132,499	'	'	6,132,499	'	'	'
Conversion of Series F Preferred to common stock	'	'	46,000	4,554,000	'	'	'
Conversion of Series F Preferred to common stock, shares	'	'	4,600,000	'	'	'	'
Forgiveness of accrued interest on note payable	195,807	'	'	195,807	'	'	'
Settlement of note payable	999,000	'	'	999,000	'	'	'
Net income (loss)	-2,882,214	'	'	'	'	'	-2,882,214
Net Unrealized gain (loss) on marketable securities	-31,367	'	'	'	'	-31,367	'
Ending Balance at Dec. 31, 2011	-30,602,223	'	306,357	166,170,855	'	-31,367	-197,048,068
Ending Balance, shares at Dec. 31, 2011	'	'	30,635,720	'	'	'	'
Conversion of convertible debentures	5,827,588	'	23,311	5,804,277	'	'	'
Conversion of convertible debentures, shares	'	'	2,331,035	'	'	'	'
Accretion of preferred stock	-21,057	'	'	-21,057	'	'	'
Buyback of common stock per share	-1,866	'	-23,311	21,445	'	'	'
Buyback of common stock per share, shares	'	'	-2,331,035	'	'	'	'
Net income (loss)	-1,645,476	'	'	'	'	'	-1,645,476
Net Unrealized gain (loss) on marketable securities	-277,837	'	'	'	'	-277,837	'
Ending Balance at Dec. 31, 2012	-26,720,871	'	306,357	171,975,520	'	-309,204	-198,693,544
Ending Balance, shares at Dec. 31, 2012	'	'	30,635,720	'	'	'	'
Net gain on debt modification	682,670	'	'	682,670	'	'	'
Accretion of preferred stock	-20,942	'	'	-20,942	'	'	'
Gain on release and sale of contingent royalty liability	16,025,000	'	'	16,025,000	'	'	'
Net income (loss)	-941,529	'	'	'	'	'	-941,529
Net Unrealized gain (loss) on marketable securities	315,854	'	'	'	'	315,854	'
Ending Balance at Dec. 31, 2013	($10,659,818)	'	$306,357	$188,662,248	'	$6,650	($199,635,073)
Ending Balance, shares at Dec. 31, 2013	'	'	30,635,720	'	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Buyback of common stock per share	$0.00	$0.00
Common Stock [Member]	'	'
Buyback of common stock per share	$0.00	$0.00
Additional Paid-In Capital [Member]	'	'
Buyback of common stock per share	$0.00	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		254 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($941,529)	($1,645,476)	($199,635,073)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'	'
Purchased in-process research and development	'	'	12,146,544
Write-off of acquired technology	'	'	3,500,000
Loss on disposition of assets	'	'	3,391
Interest expense settled through issuance of notes payable	'	'	350,500
Expenses satisfied with the issuance of stock	'	'	28,680
Forgiveness of debt	'	'	-476,837
Gain on early extinguishment of debt	'	'	-6,277,100
Non-cash gain on restricted stock valuation	'	'	-58,814
Non-cash interest expense	448,104	'	4,414,498
Non-cash charges related to options, warrants and common stock	'	'	11,115,437
Amortization of financing costs	'	'	25,188
Amortization and depreciation	1,186	1,289	2,893,141
Receipt of marketable securities	-190,000	'	-190,000
Loss on sale of marketable securities	263,154	'	263,154
Gain on sale of contingent liability	25,000	'	25,000
Changes in operating assets and liabilities:	'	'	'
(Increase) decrease in prepaid expenses and other current assets	-966	2,245	503,642
(Increase) decrease in deferred charges	3,687	-64,514	-60,827
(Decrease) increase in accounts payable and accrued expenses	-1,222,660	68,169	759,911
Increase (decrease) in accrued interest payable	5,630	432,835	8,253,262
Increase (decrease) in deferred revenue	-73,730	201,577	127,847
Increase (decrease) in current liabilities	-14,805	17,676	2,871
Increase (decrease) in other long-term liabilities	10,000	33,750	43,750
Net cash used for operating activities	-1,686,929	-952,449	-162,241,835
Cash flows from investing activities:	'	'	'
Cash acquired through Merger	'	'	1,758,037
Purchases of property and equipment	'	'	-1,654,487
Proceeds from the sale of property and equipment	'	'	3,430
Purchases of marketable securities	'	'	-132,004,923
Sales and maturities of marketable securities	884,359	'	132,889,282
Net cash provided by investing activities	884,359	'	991,339
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock	'	'	66,731,339
Buyback of common stock	'	-1,866	-28,222
Advances from related party	175,000	325,000	500,000
Net proceeds from issuance of preferred stock	'	'	39,922,170
Preferred stock conversion inducement	'	'	-600,564
Net proceeds from issuance of promissory notes	725,000	510,000	59,720,000
Proceeds from issuance of convertible debentures	'	'	9,000,000
Principal payments of notes payable/repurchase of debt	'	'	-7,750,667
Dividend payments on Series E Cumulative Convertible Preferred Stock	'	'	-516,747
Payments of financing costs	'	'	-5,612,855
Net cash provided by financing activities	900,000	833,134	161,364,454
Net (decrease) increase in cash and cash equivalents	97,430	-119,315	113,958
Cash and cash equivalents, beginning of period	16,528	135,843	'
Cash and cash equivalents, end of period	113,958	16,528	113,958
Supplemental cash flow disclosures:	'	'	'
Cash paid for interest	'	'	628,406
Supplemental disclosure of non-cash investing and financing activity:	'	'	'
Conversion of notes payable to common stock	'	5,827,588	13,000,000
Capital contribution related to forgiveness of accrued interest	'	'	6,328,306
Accrued interest reclassified in connection with conversion of Series F convertible redeemable preferred stock to common stock	'	'	640,874
Receipt of marketable securities as payment for license agreement	'	1,146,000	1,146,000
Conversion of notes payable to future royalties	'	16,000,000	16,000,000
Net change in unrealized holding gains and losses	315,854	'	315,854
Accretion of Series F preferred stock	-20,942	-21,057	-20,942
Net gain on debt modification	682,670	'	682,670
Gain on release of contingent liability	$16,000,000	'	$16,000,000

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
The Company and Summary of Significant Accounting Policies	'
	1. The Company and Summary of Significant Accounting Policies
	Alseres Pharmaceuticals, Inc. and its subsidiaries (the “Company”) is a biotechnology company engaged in the development of diagnostic products primarily for disorders in the central nervous system. The Company was founded in 1992 and merged with a publicly held company in 1995 (the “Merger”) whereby the Company changed its name to Boston Life Sciences, Inc. Effective June 7, 2007, the Company changed its name to Alseres Pharmaceuticals, Inc. During the period from inception through December 31, 2013, the Company has devoted substantially all of its efforts to business planning, raising financing, furthering the research and development of its technologies, and corporate partnering efforts. Accordingly, the Company is considered to be a “development stage enterprise” as defined in Accounting Standards Codification (ASC) 915, Development Stage Entities and will continue to be so until the commencement of commercial operations. The development stage is from October 16, 1992 (inception) through December 31, 2013.
	The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The uncertainty inherent in the need to raise additional capital and the Company’s recurring losses from operations raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Basis of Presentation
	The Company’s consolidated financial statements include the accounts of its seven subsidiaries where all of the Company’s operations are conducted. During 2012 the Company organized its seventh subsidiary, Alseres Neurodiagnostics, Inc. as a Delaware corporation. As of December 31, 2013 all of the subsidiaries were wholly-owned. All significant intercompany transactions and balances have been eliminated.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
	Cash and Cash Equivalents
	Cash equivalents are short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase. As of December 31, 2013 and 2012, cash equivalents consisted of money market funds.
	Short-term Investments
	The Company has designated its marketable securities as of each balance sheet date as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term investments based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying consolidated balance sheets. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s then current intent and ability to sell the security if it is required to do so. As of December 31, 2013, the Company’s short-term investments included 95,000 shares of common stock in Navidea Biopharmaceuticals, Inc. (Navidea or NAVB). The unrealized gain associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s cash and cash equivalents, prepaid expenses, trade payables and accrued expenses approximate their fair value due to the short-term nature of these instruments. Short-term investments consist of available-for-sale-securities as of December 31, 2013 and 2012 and are carried at fair value as disclosed in Note 11. The fair value of the Company’s long-term debt and promissory note is estimated by discounting the future cash flow using the Company’s current borrowing rates for similar types and maturities of debt. The fair value of the long term promissory note approximates the carrying value as it was issued in December of 2013.
	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years.
	Revenue Recognition
	The Company evaluates multiple element revenue arrangements under Financial Accounting Standards Board (FASB) ASC 605-25, Multiple-Element Arrangements. In addition to the form of the arrangement, the substance of the arrangement is also considered in determining whether separate agreements entered into, at or near the same time, that include elements that are interrelated or interdependent should be treated as one multiple-element arrangement. If the Company concludes that separate agreements represent one arrangement, then all the elements in the separate agreements are combined into one multiple-element arrangement for accounting purposes.
	Revenues from non-refundable license fees are recognized upon receipt of the payment if the license has stand-alone value, we do not have ongoing involvement or obligations, and we have determined the best estimate of the selling price for any undelivered items. When non-refundable license fees do not meet all of these criteria, the license revenues are recognized over the expected period of performance.
	We will periodically review our expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and license fees. We will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement. We could accelerate revenue recognition for non-refundable upfront payments or license fees in the event of an early termination of the agreements. Alternatively, we could decelerate such revenue recognition if our period of involvement is extended. While changes to such estimates have no impact on our reported cash flows, our reported revenue is significantly influenced by our estimates of the period over which our obligations are expected to be performed and, therefore, over which revenue will be recognized.
	Revenues associated with substantive, at-risk milestones pursuant to our licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in our licensing agreements that are not considered milestones will be recognized as revenue when payments are earned by our counterparties through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.
	Comprehensive Income (Loss)
	On January 1, 2012, the Company adopted the new presentation requirements under Accounting Standards Update (“ASU”) 2011-05, “Presentation of Comprehensive Income”. Comprehensive income consists of net income and other comprehensive income. Other comprehensive income includes unrealized gains and losses, net of taxes, on our marketable securities which are also recognized as separate components of equity. ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which requires an entity to separately present the amount reclassified out of accumulated other comprehensive income (AOCI) for each component of AOCI and to disclose, for each affected line item in the income statement, the amount of AOCI that has been reclassified into that line item. This information must be provided either on the face of the financial statements by income statement line item, or in a footnote. For public companies, the amendments in the update became effective for interim and annual periods beginning on or after December 15, 2012. As ASU 2013-02 and ASU 2011-05 impacted presentation only, neither had an effect on the Company’s financial position nor results of operations as of and for the years ended December 31, 2013 and 2012, respectively.
	Convertible Redeemable Shares
	In accordance with ASC 480, Distinguishing Liabilities from Equity the Company determined that since the Series F shares are mandatorily redeemable for cash or for a variable, uncapped, number of common shares, they do not qualify for equity classification.
	Income Taxes
	The Company accounts for income taxes under the liability method. Under the liability method, deferred income taxes are determined based on differences between the financial reporting and tax bases of assets and liabilities. They are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company is required to adjust its deferred tax liabilities in the period when tax rates or the provisions of the income tax laws change. Valuation allowances are established to reduce deferred tax assets to the amounts expected to be realized.

Restricted_Marketable_Securiti

Restricted Marketable Securities	12 Months Ended
	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Restricted Marketable Securities	'
	2. Restricted Marketable Securities
	Pursuant to the terms of the Amended and Restated License Agreement with Harvard University and its affiliated hospitals (Harvard) entered into on July 31, 2012, at December 31, 2013 and 2012 respectively, the Company had an obligation to transfer 5,000 and 15,000 shares of the Navidea stock to Harvard. The market value of the shares on December 31, 2013 and 2012 respectively was $10,350 and $42,450. The 5,000 shares of NAVB common stock held by the Company at December 31, 2013 is classified as restricted securities in the consolidated balance sheet and the corresponding liability is reported in other current liabilities. The Company completed the transfer of the 15,000 shares of NAVB in January 2013.

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment, Net	'
	3. Property and Equipment, net
		December 31,
		2013		2012
	Computer equipment	$	26,539	$	26,539
	Office furniture and equipment		6,738		6,738
			33,277		33,277
	Less accumulated amortization and depreciation		33,277		33,091
		$	—	$	1,186
	Amortization and depreciation expense for the year ended December 31, 2013 was approximately $1,200. Amortization and depreciation expense for the year ended December 31, 2012 was approximately $1,300. Amortization and depreciation expense for the period from inception through December 31, 2013 totaled approximately $1,655,000.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accounts Payable and Accrued Expenses	'
	4. Accounts Payable and Accrued Expenses
	The Company’s management is required to estimate accrued expenses as part of the process of preparing financial statements. Accrued expenses include the following:
		December 31, 2013		December 31, 2012
	Research and development expenses	$	470,824	$	1,339,851
	Professional fees		201,146		735,990
	General and administrative expenses		307,883		121,554
	Compensation related expenses		75,885		81,003
		$	1,055,738	$	2,278,398
	On February 15, 2013, the Company entered into Settlement Agreements with Michael Mullen and William Guinness, both members of the Board of Directors of the Company, pursuant to which the Company agreed to satisfy certain outstanding obligations to those individuals which, in aggregate, totaled $167,400 by issuing fully vest options to purchase a total of 167,400 shares of the common stock of Alseres Neurodiagnostics, Inc. ( a wholly owned subsidiary of the Company) at a purchase price to be established by the Company coincident with the closing of an equity financing for Alseres Neurodiagnostics, Inc. The options must be exercised, in whole or in part on or before February 28, 2018. The common stock issued pursuant to the exercise of the options will bear all appropriate restrictive legends on resale or disposition of the common stock. As of December 31, 2013 the options had not yet been issued nor is the closing of an equity financing certain to occur therefore the associated liability of $167,400 remains outstanding and is recorded in accrued expenses on the balance sheet at December 31, 2013. While the fair value of the options will likely be lower than the value of the current liability, the Company has determined it is not appropriate to recognize a gain at this time given the uncertainty of these events and the variability associated with the value of the options.

Deferred_Charges

Deferred Charges	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Deferred Charges	'
	5. Deferred charges
	Under the terms of the Amended and Restated License Agreement with Harvard, the Company is obligated to pay Harvard 5% of the total cash and equity considerations received as upfront sublicense payments pursuant to the sublicense agreement with Navidea. The Company recognized the $66,050 of license fees owed to Harvard as deferred charges and is amortizing these fees on a straight-line basis over the estimated performance period commensurate with the recognition of the related revenue. The deferred charges balance at December 31, 2013 and 2012, represents the unamortized portion of costs of license fees to be recognized in the future.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	6. Net Loss per share
	Basic and diluted net loss per share attributable to common stockholders has been calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.
	Stock options to purchase approximately 3.0 million shares of common stock were outstanding at December 31, 2013 and 2012, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. Common stock equivalents in the form of convertible redeemable preferred stock were not included in the calculation of net loss per share at December 31, 2013 and 2012 as their inclusion would be anti-dilutive. The exercise of stock options outstanding at December 31, 2013 could potentially dilute earnings per share in the future.

Notes_Payable_and_Debt

Notes Payable and Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable and Debt	'
	7. Notes Payable and Debt
	Effective July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007, elected to convert $16,000,000 of principal outstanding under the promissory notes to a royalty on future net sales of the Company’s Altropane product. All other rights under the Convertible Note Purchase Agreement related to the $16,000,000 of principal were waived by the lenders.
	The intent of the above convertible debt conversions and modifications was to allow for continued product development by a licensee and was considered to be the most viable option for the debt holders to recoup any of their principal. Based on these factors , these transactions were considered to be concessions and were accounted for as a troubled debt restructuring under the guidance of ASC-470-60-55. As prescribed therein, when estimates are used relating to the maximum future cash payments, as in this case, no gain shall be recognized until the estimated maximum future cash payments fall below the carrying value of the debt before restructuring.
	As of December 31, 2012, the contingent royalty liability resulting from the conversion is classified as a Level 3 liability and was reflected in the consolidated balance sheet at its fair value as a long-term liability. As is further described in Note 8, this liability was extinguished as of December 31, 2013.
	Promissory Notes — Unsecured
	Notes Payable to Significant Stockholder	December 31,
		2013		2012
	Unsecured demand note payable; interest rate of 7%: issued December 2009	$	—	$	350,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010		—		3,310,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011		—		2,240,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2012 — September 2012		—		510,000
			—		6,410,000
	Accrued interest		—		919,526
	Aggregate carrying value	$	—	$	7,329,526
	Interest expense totaling $446,104 and $432,835 was incurred related to the unsecured notes payable for the years ended December 31, 2013 and 2012, respectively.
	Through 2013, a series of working capital loans (“Borrowings”) were made to the Company by its significant stockholder, Mr. Gipson, evidenced by demand promissory notes and totaling $7,135,000 and bearing interest at 7% per annum. Interest on these notes was accrued and totaled approximately $1,365,000 at the execution date. On December 31, 2013, the Company executed a Loan Consolidation Agreement with its significant stockholder (“Lender”). The terms of the Borrowings were modified to reduce the interest to be paid and provide for a fixed due date, additional potential borrowings and a security interest in certain assets of the Company. Upon execution of the Loan Consolidation Agreement, all amounts outstanding under the Borrowings including accrued interest were cancelled and considered paid in full and the Company entered into a new Promissory Note (“Consolidated Note”).
	The Consolidated Note bears interest at 3.2% per annum payable semi-annually in arrears and requires principal to be repaid on or before December 31, 2016. The Consolidated Note also includes semi-annual cash draws for the future working capital needs of the Company. The draws will be a minimum of $110,000 and are to be added to principal when drawn. Coincident with the execution of the Loan Consolidation Agreement, the Company and the Lender also executed a Security Agreement which provides the Lender with an undivided security interest in and to all personal and intellectual property of the Company subject to all existing liens, encumbrances and license rights previously granted by the Company. The Security Agreement also allows the Company to be free to dispose of or liquidate the collateral without any prior waiver or authorization from the Lender so long as the proceeds of any such disposition are used to pay down the principal on the Consolidated Note or the Lender affirmatively waives such obligation in writing.
	The Company considered whether the transaction was within the scope of ASC 470-60-55 Accounting for Troubled Debt Restructuring, which states that if a Company is experiencing financial difficulties and a concession is granted, troubled debt restructuring accounting should be applied. The Company has concluded that it is experiencing financial difficulties and the creditor has granted a concession as the effective borrowing rate for the restructured debt is less than the effective rate of told debt prior to restructuring. The Company has recognized a gain of $682,670 equal to the difference between the carrying value of the old debt and the present value of the future cash flows under the new terms. Since the lender is a related party, the gain was considered to be in essence a capital transaction and therefore, the gain was recognized as an addition to additional paid in capital. Additionally, due to this restructuring, future payments made will be charged to the carrying value of the restructured debt balance and no interest expense will be recorded going forward.

Contingent_Royalty_Liability

Contingent Royalty Liability	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Contingent Royalty Liability	'
	8. Contingent Royalty Liability
	Effective July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007 and herein referred to as the prior lenders, elected to convert $16,000,000 of principal outstanding under the promissory notes to a royalty on future net sales of the Company’s Altropane product.
	On December 31, 2013 the Company entered into a Release of Liability Agreement with the prior lenders referenced above pursuant to which the prior lenders unconditionally released the Company from any and all liability to pay any royalties to them on future sales of Altropane.
	Coincident with the execution of the Release of Liability Agreement with the prior lenders, the Company entered into a Purchase and Sale Agreement with Royalty Realization IV, LLC, a related party, that was created for the purpose of collecting royalties and paying them to the prior lenders, also related parties. The sole member of Royalty Realization IV, LLC is one of the three general partners of Ingalls & Snyder Value Partners LP. Ingalls & Snyder Value Partners LP is a related party as it is one of the prior lenders and the Company’s major shareholder and lender, Mr. Gipson, is also one of its three general partners. Neither of these general partners own more than 10% of Ingalls & Snyder Value Partners LP. The agreement provides that, in exchange for $25,000 cash consideration to the Company, Royalty Realization IV, LLC agreed to pay 8% royalties on future sales of Altropane to the prior lenders and the Company agreed to instruct Navidea to pay the 8% royalty due to the Company directly to Royalty Realization IV if and when such royalty is earned by the Company.
	At December 31, 2013 the Company no longer carried any long-term contingent liability on its balance sheet and eliminated any requirement to estimate the value of such contingent liability. Since the prior lenders and Royalty Realization IV, LLC are considered related parties, the associated gain and consideration received were considered to be in essence capital transactions and therefore, were recognized as increases to additional paid in capital.

Revenue_Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Revenue Recognition	'
	9. Revenue Recognition
	Our revenues have been generated primarily through sublicense and option agreements related to our Altropane product. The terms of these agreements generally contain multiple elements, or deliverables, which have included (i) licenses or options to obtain licenses to our technology; (ii) technology transfer obligations related to the licenses and (iii) research, development, regulatory and commercialization activities to be performed on our behalf. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, up-front license fees; option exercise fees; milestone payments; and royalties on future product sales.
	The Company evaluates multiple element revenue arrangements under FASB ASC 605-25, Multiple-Element Arrangements as described in Note 1.
	Option Agreement with Navidea
	On January 19, 2012 the Company entered into an Option Agreement with Navidea, to license [123I]-E-IAFCT Injection (also referred to as Altropane), an Iodine-123 radio labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Under the terms of the option agreement, Navidea paid the Company a non-refundable option fee of $500,000 upon signing the exclusive right to negotiate a definitive license agreement by June 30, 2012 with a no-fee extension of the diligence period through July 31, 2012 available to Navidea. The option agreement provided Navidea with exclusive rights to license the asset and complete further diligence and prepare the documentation necessary to enter into a definitive license agreement for Altropane. Our deliverables through June 30, 2012 were to provide assistance to Navidea with regards to meetings and communications with the Food and Drug Administration (FDA) to allow Navidea to evaluate a path to commercialization and the feasibility of exercising the license option. As such we determined that the $500,000 non-refundable option fee received from Navidea represented a unit of accounting separate from scheduled milestone payments that would be receivable should the license option be exercised. Therefore the Company recognized the non-refundable option fee received from Navidea ratably over the option period which ended June 30, 2012 as the Company had continuing performance obligations through that date. Regulatory feedback received in June caused Navidea to extend their diligence review through July 31, 2012 which they elected to do ahead of executing a license on July 31, 2012. The extension of diligence into July created no additional obligations on Alseres beyond those completed by June 30, so no adjustment to revenue was required as a result of the extension by Navidea.
	Sublicense Agreement with Navidea
	Effective July 31, 2012 the Company entered into an exclusive, worldwide sublicense agreement with Navidea for the research, development and commercialization of Altropane. Altropane is an iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.
	The Company concluded that the Sublicense Agreement entered into with Navidea effective July 31, 2012, should be accounted for as a single unit of accounting in accordance with the rules set forth in FASB ASC 605-25. These transactions are described in greater detail in Note 13 of these Consolidated Financial Statements.
	The Company’s deliverables under the Sublicense Agreement with Navidea include granting a license of rights and transferring technology (“know-how”) related to Altropane. The Company determined that pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the granting of a license of rights and the transfer of technology (“know-how”) related to Altropane were not separable and, accordingly, are being treated as a single unit of accounting. The Company applied the guidance in ASC 605 Revenue Recognition, to determine the appropriate revenue recognition period for the upfront sublicense execution payment received from Navidea. Advance payments received in excess of amounts earned are classified as deferred revenue until earned. The upfront sublicense execution payment of $175,000 in cash and the market value of $1,146,000 for the 300,000 shares of Navidea common stock as of July 31, 2012 were recorded as deferred revenue. Revenue will be recognized ratably from the date the sublicense agreement became effective on July 31, 2012, through the expected life of the last to expire issued and sublicensed U.S. patent for Altropane in June 2030.
	As of December 31, 2013 and 2012, unearned revenue of $73,731 and $73,730 is reflected as a current liability and $1,142,816 and $1,216,547 is classified as a long-term liability in the consolidated balance sheet respectively.
	The sublicense agreement also provides for contingent milestone payments to the Company of up to $2.9 million and the issuance of up to an additional 1.15 million shares of Navidea common stock. Milestone payments of $2.5 million and the issuance of 550,000 shares of Navidea common stock will occur at the time of product registration. The Company will be issued an additional 400,000 shares of Navidea common stock when certain cumulative net sales of the approved product are achieved. In addition, the license terms anticipate royalties on yearly net sales of the approved product, ranging from 10% to 14% of commercial net sales based on the sales price per dose, which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met. Per the Amended and Restated License Agreement with Harvard, the Company is obligated to pay Harvard 5% of Milestone payments and 2% of royalties, if earned.

Stockholders_Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Deficit	'
	10. Stockholders’ Deficit
	Common Stock
	On December 31, 2012 the Company agreed to purchase 537,931 shares of common stock held by Arthur Koenig and 1,793,104 shares of common stock held by Ingalls and Snyder Value Partners, LP at a purchase price per share of $0.0008 for total payment of $1,864. The closing price for the Company’s stock on December 27th was $0.08 per share.
	For the year ended December 31, 2012, the Company had repurchased a total of 2,331,035 shares of its common stock and applied the constructive retirement method to these shares. The constructive retirement method was applied to these shares as management does not intend to reissue the shares within a reasonable period of time. The aggregate value of the shares reacquired in 2012 was $23,310. This amount has been charged to the common stock account.
	Preferred Stock
	The Company authorized 1,000,000 shares of preferred stock of which 25,000 shares have been designated as Series A Convertible Preferred Stock, 500,000 shares have been designated as Series D Convertible Preferred Stock, and 800 shares have been designated as Series E Cumulative Convertible Preferred Stock (the “Series E Stock”). In March 2009, the Company designated 200,000 shares as Series F Convertible Preferred Stock (“Series F Stock”). The remaining authorized shares have not been designated.
	Convertible Preferred Stock
	In 2009 the Company issued a total of 196,000 shares of Series F convertible preferred stock to Mr. Gipson and received gross proceeds of $4,900,000. On June 1, 2011 the Company issued to Mr. Gipson 4,600,000 shares of its common stock in exchange for the conversion by Mr. Gipson of 184,000 shares of the Company’s Series F Convertible, Redeemable Preferred Stock (“Series F Stock”). Each share of the Series F Stock was converted into 25 shares of common stock pursuant to the conversion terms of the Series F Stock contained in the Certificate of Designation for the Series F Stock. The cumulative accrued interest at the date of conversion of $640,874 was reclassified to additional paid-in capital since the shares were no longer redeemable. As of December 31, 2013 there remained 12,000 shares of Series F Stock outstanding and held by Mr. Gipson.
	The key terms of the Series F Stock are summarized below:
	Dividend: The Series F Stock is entitled to receive any dividend that is paid to holders of our common stock. Any subdivisions, combinations, consolidations or reclassifications to the common stock must also be made accordingly to Series F Stock, respectively.
	Liquidation Preference: In the event of our liquidation, dissolution or winding up, before any payments are made to holders of our common stock or any other class or series of our capital stock ranking junior as to liquidation rights to the Series F Stock, the holders of the Series F Stock will be entitled to receive the greater of (i) $25.00 per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares) plus any outstanding and unpaid dividends thereon and (ii) such amount per share as would have been payable had each share been converted into common stock. After such payment to the holders of Series F Stock and the holders of shares of any other series of our preferred stock ranking senior to the common stock as to distributions upon liquidation, the remaining our assets will be distributed pro rata to the holders of our common stock.
	Voting Rights: Each share of Series F Stock shall entitle its holder to a number of votes equal to the number of shares of our common stock into which such share of Series F Stock is convertible.
	Conversion: Each share of Series F Stock is convertible at the option of the holder thereof at any time. Each share of Series F Stock is initially convertible into 25 shares of common stock, subject to adjustment in the event of certain dividends, stock splits or stock combinations affecting the Series F Stock or the common stock, and subject to adjustment on a weighted-average basis in the event of certain issuances by us of securities for a price less than the then-current price at which the Series F Stock converts into common stock.
	Redemption: At any time after September 1, 2011, any holder of Series F Stock may elect to have some or all of such shares redeemed by us at a price equal to the aggregate of (i) $25 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares), or the Original Issue Price, plus (ii) all declared but unpaid dividends thereon, plus (iii) an amount computed at a rate per annum of 7% of the Original Issue Price from March 19, 2009 until the redemption date. No redemption demand has been made as of December 31, 2013.
	Accretion: The terms of the Series F Stock contain provisions that may require redemption in circumstances that are beyond the Company’s control. Therefore, the shares have been recorded, net of issuance costs of approximately $25,000, as convertible, redeemable stock outside of permanent equity. The Series F Stock was recorded at fair value on the date of issuance. For the year ended December 31, 2013, the Company recorded approximately $20,942 in accretion on the outstanding Series F Stock.
	Stock Option Plans
	The Company can issue both nonqualified and incentive stock options to employees, officers, consultants and scientific advisors of the Company under the Amended and Restated 2005 Stock Incentive Plan (the “2005 Plan”). At December 31, 2009, the 2005 Plan provided for the issuance of options, restricted stock, restricted stock units, stock appreciation rights or other stock-based awards to purchase 3,050,000 shares of the Company’s common stock. The 2005 Plan contains a provision that allows for an annual increase in the number of shares available for issuance under the 2005 Plan on the first day of each of the Company’s fiscal years during the period beginning in fiscal year 2006 and ending on the second day of fiscal year 2014. The annual increase in the number of shares shall be equal to the lowest of 400,000 shares; 4% of the Company’s outstanding shares on the first day of the fiscal year; and an amount determined by the Board of Directors. No adjustment to the 2005 Plan was made on January 1, 2013.
	The Company also has outstanding stock options in three other stock option plans, the 1998 Omnibus Plan, the Amended and Restated Omnibus Stock Option Plan and the Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan. All plans have expired and no future issuance of awards is permissible.
	We use the Black-Scholes option-pricing model to calculate the fair value of each option grant on the date of grant. No stock options were granted during the years ended December 31, 2013 and 2012. All stock options outstanding at December 3, 2013 and 2012 were fully vested, therefore no unrecognized stock compensation expense was recorded at either date.
	Stock Options
	The following table summarizes the options issued and outstanding as of December 31, 2013:
		Shares			Weighted-Average
					Exercise Price
	Outstanding stock options at the beginning of year		3,010,980		$	1.51
	Granted		—			—
	Exercised		—			—
	Forfeited and expired		(8,500	)		5
	Outstanding and exercisable stock options at year end		3,002,480		$	1.5
	The following table summarizes information about the stock options outstanding and exercisable as of December 31, 2013:
	Range of Exercise Prices	Number Outstanding			Weighted Average remaining		Weighted Average
					Contractual Life		Exercise Price
	$1.15 — $1.36		2,287,500			.4 years	$	1.15
	$2.00 — $3.00		539,980			1.7 years		2.33
	$3.10 — $4.65		155,000			3.8 years		3.17
	$4.99 — $6.96		20,000			.3 years		5.68
			3,002,480			0.8 years	$	1.5
	As of December 31, 2013, 809,172 shares were available for grant under the 2005 Plan. As of December 31, 2013, the Company had reserved 3,811,652 shares of common stock to meet its option obligation.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	11. Fair Value Measurements
	The fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels:
	Level 1 — unadjusted quoted prices in active markets for identical securities;
	Level 2 — unadjusted quoted prices in markets that are not active,
	Level 3 — significant unobservable inputs, including our own assumptions in determining fair value
	The following table summarizes the financial assets that we measured at fair value as of:
		December 31, 2013
		Level 1		Level 2		Level 3		Total
	Available for sale securities	$	196,650	$	—	$	—	$	196,650
	Total assets	$	196,650	$	—	$	—	$	196,650
		31-Dec-12
		Level 1		Level 2		Level 3		Total
	Available for sale securities	$	838,309	$	—	$	—	$	838,309
	Total assets	$	838,309	$	—	$	—	$	838,309
	Contingent royalty		—	$	—	$	16,000,000	$	16,000,000
	Total liabilities		—	$	—	$	16,000,000	$	16,000,000
	As of December 31, 2013, the Company’s Level 1 short term investments consisted of 95,000 shares of Navidea common stock which are traded on the NYSE under the symbol NAVB.
	As of December 31, 2012, the Company’s Level 1 short-term investments consisted of 285,000 shares of Navidea common stock which are traded on the NYSE under the symbol NAVB and 39,209 shares of FluoroPharma Medical, Inc. common stock which are traded on the OTX Bulletin Board (“OTCBB”) under the symbol FPMI.
	A contingent royalty liability which resulted from the election by certain purchasers of the Company’s Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) to convert a total of $16,000,000 in debt obligation into a right to receive future royalties on net sales of the Company’s molecular imaging products. The Company obtained a third party fair value valuation for its contingent royalty liability as of December 31, 2012. The fair value measurement is based on significant inputs not observable in the market, which require it to be reported as a Level 3 asset within the fair value hierarchy. The valuation uses assumptions that the Company believes would be made by a market participant. In particular, the valuation analysis employed the income approach based on the sum of the economic income that an asset is anticipated to produce in the future. In this case that asset is the potential royalty income to be paid to the Company by Navidea as a result of the license agreement for Altropane. The discounted cash flow method of the income approach was chosen as the method best suited to valuing the contingent royalty liability. Changes in the fair value of the contingent royalty liability will be reflected in the consolidated statements of comprehensive income in the period they become known. As further detailed in Note 8, this liability was extinguished as of December 31, 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	12. Income Taxes
	As of December 31, 2013, the Company had federal and state net operating loss (“NOL”) carryforwards of approximately $61,516,000 and $27,325,000, respectively and federal and Massachusetts state research and development (“R&D”) credit carryforwards of approximately $1,578,000 and $1,110,000, respectively subject to limitation, may be available to offset future federal and state income tax liabilities through 2031.
	Deferred tax assets consisted of the following as of December 31:	2013			2012
	Net operating loss carryforward	$	22,952,000		$	31,338,000
	Capitalized research and development expenses		6,055,000			10,402,000
	License fees		277,000			325,000
	Stock-based compensation expense		2,264,000			2,264,000
	Other		547,000			737,000
	Gross deferred tax assets		32,095,000			45,066,000
	Valuation allowance		(32,095,000	)		(45,066,000	)
	Net deferred tax assets	$	—		$	—
	A reconciliation of the amount of reported tax benefit and the amount computed using the U.S. federal statutory rate of 35% for the years ended December 31 is as follows:
		2013			2012
	Tax provision (benefit) at statutory rate	$	(321,000	)	$	(1,009,000	)
	State taxes, net of federal benefit		985,000			267,000
	Expiring state net operating loss carryforward		—			455,000
	Gain on forgiven interest and cancellation of debt and other		2,567,000			2,567,000
	Decrease in valuation allowance		(6,731,000	)		(5,080,000	)
	Permanent items		6,069,000			2,800,000
		$	—		$	—
	For the years ended December 31, 2013 and 2012, the Company did not record any federal or state tax expense given its continued net operating loss position. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which are comprised principally of net operating losses (“NOL”) and capitalized research and development expenditures. Management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance has been recorded.
	Income tax benefit for the years ended December 31:	2013			2012
	Federal	$	3,574,000		$	(2,737,000	)
	State		817,000			(645,000	)
			4,391,000			(3,382,000	)
	Valuation allowance		(4,391,000	)		3,382,000
		$	—		$	—
	A reconciliation of the unrecognized tax benefits recorded for the years ended December 31 is as follows:
		2013			2012
	Balance at January 1	$	2,822,531		$	2,822,531
	Additions based on tax positions related to the current year		—			—
	Balance at December 31	$	2,822,531		$	2,822,531
	The balance of unrecognized tax benefits as of December 31, 2013 of approximately $2,822,531 are tax benefits that, if recognized, would not affect the Company’s effective tax rate since they are subject to a full valuation allowance.
	The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company has no accrual for interest and penalties as of December 31, 2013.
	The Company is subject to both federal and state income tax for the jurisdiction within which it operates. Within these jurisdictions, the Company is open to examination for tax years ended December 31, 2010 through December 31, 2013. The U.S. Internal Revenue Service (IRS) had completed an audit of tax years 2007 and 2008 and had informed us that no adjustments to the federal tax returns as filed would be proposed as a result of the audit. However, because we are carrying forward income tax attributes such as the NOL from 2006, these attributes can still be audited when utilized on returns filed in the future.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	13. Commitments and Contingencies
	In August 2013 the Company vacated its offices in Hopkinton, MA and is currently occupying approximately 200 square feet of office space in Auburndale, MA as a tenant at will on a shared basis at $500 per month. Total rent expense was approximately $25,800, $2,500 of which is for the Auburndale space and $71,500 for the years ended December 31, 2013 and 2012, respectively and approximately $4,141,300 for the period from inception (October 16, 1992) through December 31, 2013.
	On March 13, 2012 the Company received notice that Boston Children’s Hospital and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs.
	On February 1, 2013 the Company entered into a Settlement Agreement and Release with Boston Children’s Hospital (BCH) and Children’s Medical Center Corporation (CMCC) in full settlement of the lawsuit filed by BCH and CMCC seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906 plus costs.
	In settlement of all claims by BCH and CMCC, the Company agreed to pay a lump sum of One Hundred Eighty five Thousand dollars ($185,000) to the plaintiffs. In addition to the lump sum payment, the Company agreed to pay to the plaintiffs an additional sum equal to the then cash value of 20,000 shares of the common stock of Navidea upon the occurrence of the first milestone described in Section 4.2 of the sublicense agreement dated as of July 31, 2012 between Navidea and the Company. The milestone occurred in December, 2013 at which time the value of 20,000 shares of Navidea common stock was $40,000. The Company paid CMCC the sum of $40,000 in January 2014 in accordance with the terms of the Settlement Agreement and Release.
	On May 2, 2012 the Company received notice that Biostorage Technologies, Inc (Biostorage) had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. On July 27 , 2013, the Company entered into a settlement agreement with Biostorage pursuant to which the Company agreed to pay a total of $75,000 to Biostorage in three installments as follows: $10,000 on July 31, 2013, $40,000 December 31, 2013 and $25,000 February 28, 2014. The Company also agreed to stipulate a judgment in the amount of $95,000 to be adjusted down by each payment actually made by the Company and so long as each required payment is made by the Company on time, the judgment will be vacated on February 28, 2014. As of December 31, 2013 the Company had paid the entire $75,000 settlement amount in full and therefore recognized the remaining $20,000 as a gain which is reported in other income.
	Sublicense Agreement with Navidea
	Effective July 31, 2012, the Company entered into an exclusive, worldwide sublicense agreement with Navidea for the research, development and commercialization of Altropane. Altropane is an Iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders as described in Note 9.
	Either party may terminate the agreement if the other party materially breaches the agreement and such breach remains uncured for 60 days after the date of notice of such breach. Navidea has the right to terminate the agreement at any time for any or no reason, in part or in its entirety, upon providing sixty day notice to the Company. If neither party terminates the agreement, then the agreement will remain in effect until the occurrence of the last royalty expiration date as such term is defined in the sublicense agreement.
	Amended and Restated License Agreement with Harvard
	Simultaneous with the signing of the Navidea Sublicense Agreement in July 2012, the Company entered into an Amended and Restated License Agreement with Harvard which resulted in the revision of certain financial terms regarding the royalty payable to Harvard, the percentage of non-royalty income payable to Harvard by the Company and the timing of said payments. Pursuant to the agreement, the Company is obligated to make a cash payment of $8,750 to Harvard in connection with the receipt of the cash consideration of $175,000 received from Navidea upon execution of the sublicense agreement. This payment is due to Harvard within 30 days following the first commercial sale of the Altropane product. The Company was also obligated to transfer to Harvard 15,000 shares of the Navidea common stock received as part of the sublicense agreement to Harvard. The shares were transferred during January 2013. As result of the receipt by the Company of the first milestone payment from Navidea in December 2013, the Company is obligated to transfer 5,000 shares of the Navidea common stock received by the Company. These shares will be transferred upon the effectiveness of an S-3 registration statement to be filed by Navidea covering the shares issued. In addition, the Company is obligated to make a cash payment of $10,000 to Harvard in connection with the receipt of the cash milestone of $200,000 received from Navidea. This payment is due to Harvard within 30 days following the first commercial sale of the Altropane product.
	Guarantor Arrangements
	The Company has entered into agreements to indemnify its executive officers and directors for certain events or occurrences while the officer or director is, or was serving, at the Company’s request in such capacity. The indemnification period is for the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits the Company’s exposure and enables the Company to recover a portion of any future amounts paid. As a result of the Company’s insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	14. Related Party Transactions
	From September 2012 through December 2013, Mr. Gipson provided a total of $500,000 to the Company as an advance against his planned purchase of stock in Alseres Neurodiagnostics, Inc. These funds were available to the Company for use during 2012 and 2013 and the advance is reflected as advances from related parties on the consolidated balance sheet.
	Additional Related Party Transactions during 2013 are disclosed in footnotes 7, 8 and 10.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	15. Subsequent Events
	The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. During this period, the Company did not identify any material events that require accounting or disclosure in these financial statements.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The Company’s consolidated financial statements include the accounts of its seven subsidiaries where all of the Company’s operations are conducted. During 2012 the Company organized its seventh subsidiary, Alseres Neurodiagnostics, Inc. as a Delaware corporation. As of December 31, 2013 all of the subsidiaries were wholly-owned. All significant intercompany transactions and balances have been eliminated.
Use of Estimates	'
	.Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash equivalents are short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase. As of December 31, 2013 and 2012, cash equivalents consisted of money market funds.
Short-Term Investments	'
	Short-term Investments
	The Company has designated its marketable securities as of each balance sheet date as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term investments based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying consolidated balance sheets. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s then current intent and ability to sell the security if it is required to do so. As of December 31, 2013, the Company’s short-term investments included 95,000 shares of common stock in Navidea Biopharmaceuticals, Inc. (Navidea or NAVB). The unrealized gain associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s cash and cash equivalents, prepaid expenses, trade payables and accrued expenses approximate their fair value due to the short-term nature of these instruments. Short-term investments consist of available-for-sale-securities as of December 31, 2013 and 2012 and are carried at fair value as disclosed in Note 11. The fair value of the Company’s long-term debt and promissory note is estimated by discounting the future cash flow using the Company’s current borrowing rates for similar types and maturities of debt. The fair value of the long term promissory note approximates the carrying value as it was issued in December of 2013.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years.
Revenue Recognition	'
	Revenue Recognition
	The Company evaluates multiple element revenue arrangements under Financial Accounting Standards Board (FASB) ASC 605-25, Multiple-Element Arrangements. In addition to the form of the arrangement, the substance of the arrangement is also considered in determining whether separate agreements entered into, at or near the same time, that include elements that are interrelated or interdependent should be treated as one multiple-element arrangement. If the Company concludes that separate agreements represent one arrangement, then all the elements in the separate agreements are combined into one multiple-element arrangement for accounting purposes.
	Revenues from non-refundable license fees are recognized upon receipt of the payment if the license has stand-alone value, we do not have ongoing involvement or obligations, and we have determined the best estimate of the selling price for any undelivered items. When non-refundable license fees do not meet all of these criteria, the license revenues are recognized over the expected period of performance.
	We will periodically review our expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and license fees. We will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement. We could accelerate revenue recognition for non-refundable upfront payments or license fees in the event of an early termination of the agreements. Alternatively, we could decelerate such revenue recognition if our period of involvement is extended. While changes to such estimates have no impact on our reported cash flows, our reported revenue is significantly influenced by our estimates of the period over which our obligations are expected to be performed and, therefore, over which revenue will be recognized.
	Revenues associated with substantive, at-risk milestones pursuant to our licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in our licensing agreements that are not considered milestones will be recognized as revenue when payments are earned by our counterparties through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	On January 1, 2012, the Company adopted the new presentation requirements under Accounting Standards Update (“ASU”) 2011-05, “Presentation of Comprehensive Income”. Comprehensive income consists of net income and other comprehensive income. Other comprehensive income includes unrealized gains and losses, net of taxes, on our marketable securities which are also recognized as separate components of equity. ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which requires an entity to separately present the amount reclassified out of accumulated other comprehensive income (AOCI) for each component of AOCI and to disclose, for each affected line item in the income statement, the amount of AOCI that has been reclassified into that line item. This information must be provided either on the face of the financial statements by income statement line item, or in a footnote. For public companies, the amendments in the update became effective for interim and annual periods beginning on or after December 15, 2012. As ASU 2013-02 and ASU 2011-05 impacted presentation only, neither had an effect on the Company’s financial position nor results of operations as of and for the years ended December 31, 2013 and 2012, respectively.
Convertible Redeemable Shares	'
	Convertible Redeemable Shares
	In accordance with ASC 480, Distinguishing Liabilities from Equity the Company determined that since the Series F shares are mandatorily redeemable for cash or for a variable, uncapped, number of common shares, they do not qualify for equity classification.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the liability method. Under the liability method, deferred income taxes are determined based on differences between the financial reporting and tax bases of assets and liabilities. They are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company is required to adjust its deferred tax liabilities in the period when tax rates or the provisions of the income tax laws change. Valuation allowances are established to reduce deferred tax assets to the amounts expected to be realized.
Accounting for Troubled Debt Restructuring	'
	The Company considered whether the transaction was within the scope of ASC 470-60-55 Accounting for Troubled Debt Restructuring, which states that if a Company is experiencing financial difficulties and a concession is granted, troubled debt restructuring accounting should be applied. The Company has concluded that it is experiencing financial difficulties and the creditor has granted a concession as the effective borrowing rate for the restructured debt is less than the effective rate of told debt prior to restructuring.

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment, Net	'
		December 31,
		2013		2012
	Computer equipment	$	26,539	$	26,539
	Office furniture and equipment		6,738		6,738
			33,277		33,277
	Less accumulated amortization and depreciation		33,277		33,091
		$	—	$	1,186

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Summary of Accounts Payable and Accrued Expenses	'
		December 31, 2013		December 31, 2012
	Research and development expenses	$	470,824	$	1,339,851
	Professional fees		201,146		735,990
	General and administrative expenses		307,883		121,554
	Compensation related expenses		75,885		81,003
		$	1,055,738	$	2,278,398

Notes_Payable_and_Debt_Tables

Notes Payable and Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Summary of Notes Payable to Significant Stockholder	'
	Promissory Notes — Unsecured
	Notes Payable to Significant Stockholder	December 31,
		2013		2012
	Unsecured demand note payable; interest rate of 7%: issued December 2009	$	—	$	350,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010		—		3,310,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011		—		2,240,000
	Unsecured demand notes payable; interest rate of 7%: issued January 2012 — September 2012		—		510,000
			—		6,410,000
	Accrued interest		—		919,526
	Aggregate carrying value	$	—	$	7,329,526

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Summary of Options Issued and Outstanding	'
	The following table summarizes the options issued and outstanding as of December 31, 2013:
		Shares			Weighted-Average
					Exercise Price
	Outstanding stock options at the beginning of year		3,010,980		$	1.51
	Granted		—			—
	Exercised		—			—
	Forfeited and expired		(8,500	)		5
	Outstanding and exercisable stock options at year end		3,002,480		$	1.5
Summarizes Information about the Stock Options Outstanding and Exercisable	'
	The following table summarizes information about the stock options outstanding and exercisable as of December 31, 2013:
	Range of Exercise Prices	Number Outstanding			Weighted Average remaining		Weighted Average
					Contractual Life		Exercise Price
	$1.15 — $1.36		2,287,500			.4 years	$	1.15
	$2.00 — $3.00		539,980			1.7 years		2.33
	$3.10 — $4.65		155,000			3.8 years		3.17
	$4.99 — $6.96		20,000			.3 years		5.68
			3,002,480			0.8 years	$	1.5

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Summary of Financial Asset Measured at Fair Value	'
	The following table summarizes the financial assets that we measured at fair value as of:
		December 31, 2013
		Level 1		Level 2		Level 3		Total
	Available for sale securities	$	196,650	$	—	$	—	$	196,650
	Total assets	$	196,650	$	—	$	—	$	196,650
		31-Dec-12
		Level 1		Level 2		Level 3		Total
	Available for sale securities	$	838,309	$	—	$	—	$	838,309
	Total assets	$	838,309	$	—	$	—	$	838,309
	Contingent royalty		—	$	—	$	16,000,000	$	16,000,000
	Total liabilities		—	$	—	$	16,000,000	$	16,000,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Summary of Deferred Tax Assets	'
	Deferred tax assets consisted of the following as of December 31:	2013			2012
	Net operating loss carryforward	$	22,952,000		$	31,338,000
	Capitalized research and development expenses		6,055,000			10,402,000
	License fees		277,000			325,000
	Stock-based compensation expense		2,264,000			2,264,000
	Other		547,000			737,000
	Gross deferred tax assets		32,095,000			45,066,000
	Valuation allowance		(32,095,000	)		(45,066,000	)
	Net deferred tax assets	$	—		$	—
Summary of Reported Tax Benefit and Amount Computed Using U.S. Federal Statutory Rate	'
	A reconciliation of the amount of reported tax benefit and the amount computed using the U.S. federal statutory rate of 35% for the years ended December 31 is as follows:
		2013			2012
	Tax provision (benefit) at statutory rate	$	(321,000	)	$	(1,009,000	)
	State taxes, net of federal benefit		985,000			267,000
	Expiring state net operating loss carryforward		—			455,000
	Gain on forgiven interest and cancellation of debt and other		2,567,000			2,567,000
	Decrease in valuation allowance		(6,731,000	)		(5,080,000	)
	Permanent items		6,069,000			2,800,000
		$	—		$	—
Summary of Income Tax Benefit	'
	Income tax benefit for the years ended December 31:	2013			2012
	Federal	$	3,574,000		$	(2,737,000	)
	State		817,000			(645,000	)
			4,391,000			(3,382,000	)
	Valuation allowance		(4,391,000	)		3,382,000
		$	—		$	—
Reconciliation of Unrecognized Tax Benefits	'
	A reconciliation of the unrecognized tax benefits recorded for the years ended December 31 is as follows:
		2013			2012
	Balance at January 1	$	2,822,531		$	2,822,531
	Additions based on tax positions related to the current year		—			—
	Balance at December 31	$	2,822,531		$	2,822,531

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Subsidiaries
Accounting Policies [Line Items]	'
Number of consolidated subsidiaries	7
Period of maturity on conversion of cash equivalents	'90 days
NAVB Stock [Member]	'
Accounting Policies [Line Items]	'
Number of common stock include in Short-term investments	95,000
Minimum [Member]	'
Accounting Policies [Line Items]	'
Estimated useful lives of the assets	'3 years
Maximum [Member]	'
Accounting Policies [Line Items]	'
Estimated useful lives of the assets	'5 years

Restricted_Marketable_Securiti1

Restricted Marketable Securities - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Investments Debt And Equity Securities [Abstract]	'	'	'
Number of shares obligation/completed to transfer	15,000	5,000	15,000
Market value of the shares	'	$10,350	$42,450

Property_and_Equipment_Net_Sum

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$33,277	$33,277
Less accumulated amortization and depreciation	33,277	33,091
Property and equipment, total	'	1,186
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	26,539	26,539
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$6,738	$6,738

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	12 Months Ended		254 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'	'	'
Amortization and depreciation expense	$1,186	$1,289	$2,893,141

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Payable And Accrued Liabilities Current [Line Items]	'	'
Accounts payable and accrued expenses	$1,055,738	$2,278,398
Research and Development Expenses [Member]	'	'
Accounts Payable And Accrued Liabilities Current [Line Items]	'	'
Accounts payable and accrued expenses	470,824	1,339,851
Professional Fees [Member]	'	'
Accounts Payable And Accrued Liabilities Current [Line Items]	'	'
Accounts payable and accrued expenses	201,146	735,990
General and Administrative Expenses [Member]	'	'
Accounts Payable And Accrued Liabilities Current [Line Items]	'	'
Accounts payable and accrued expenses	307,883	121,554
Compensation Related Expenses [Member]	'	'
Accounts Payable And Accrued Liabilities Current [Line Items]	'	'
Accounts payable and accrued expenses	$75,885	$81,003

Accounts_Payable_and_Accrued_E3

Accounts Payable and Accrued Expenses - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 15, 2013
Payables And Accruals [Abstract]	'	'
Vested options to purchase of common stock	'	$167,400
Vested options to purchase of common stock, Shares	'	167,400
Options exercised expiration date	28-Feb-18	'
Outstanding liability under settlement agreement	$167,400	'

Deferred_Charges_Additional_In

Deferred Charges - Additional Information (Detail) (USD $)	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Total license fees related to cash and stock consideration received	$66,050
Cash and equity considerations obligation percent	5.00%

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'
Number of antidilutive securities excluded from computation of diluted net loss per common share, amount	3	3

Notes_Payable_and_Debt_Additio

Notes Payable and Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	254 Months Ended	12 Months Ended
	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
				Subsequent Event [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Convertible promissory notes	$16,000,000	$16,000,000	'	'	'	'
Interest expense	'	'	'	0	446,104	432,835
Promissory notes demanded	'	7,135,000	7,135,000	'	'	'
Interest rate on promissory notes	'	7.00%	7.00%	'	'	'
Total accrued interest	'	1,365,000	1,365,000	'	'	'
Interest rate on new note payable semi-annually in arrears	'	3.20%	3.20%	'	'	'
Principal due date	'	31-Dec-16	'	'	'	'
Minimum draw amount	'	110,000	110,000	'	'	'
Recognized gain	'	$682,670	$682,670	'	'	'

Notes_Payable_and_Debt_Summary

Notes Payable and Debt - Summary of Notes Payable to Significant Stockholder (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Short-term Debt [Line Items]	'	'
Demand notes payable value	'	$6,410,000
Accrued interest	5,630	919,526
Aggregate carrying value	'	7,329,526
Unsecured Demand Note Payable; Interest Rate of 7%: Issued December 2009 [Member]	'	'
Short-term Debt [Line Items]	'	'
Demand notes payable value	'	350,000
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2010 - December 2010 [Member]	'	'
Short-term Debt [Line Items]	'	'
Demand notes payable value	'	3,310,000
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2011 - December 2011 [Member]	'	'
Short-term Debt [Line Items]	'	'
Demand notes payable value	'	2,240,000
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2012 - September 2012 [Member]	'	'
Short-term Debt [Line Items]	'	'
Demand notes payable value	'	$510,000

Notes_Payable_and_Debt_Summary1

Notes Payable and Debt - Summary of Notes Payable to Significant Stockholder (Parenthetical) (Detail)	Dec. 31, 2013	Dec. 31, 2012
Short-term Debt [Line Items]	'	'
Interest rate of notes payable	7.00%	'
Unsecured Demand Note Payable; Interest Rate of 7%: Issued December 2009 [Member]	'	'
Short-term Debt [Line Items]	'	'
Interest rate of notes payable	7.00%	7.00%
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2010 - December 2010 [Member]	'	'
Short-term Debt [Line Items]	'	'
Interest rate of notes payable	7.00%	7.00%
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2011 - December 2011 [Member]	'	'
Short-term Debt [Line Items]	'	'
Interest rate of notes payable	7.00%	7.00%
Unsecured Demand Notes Payable; Interest Rate of 7%: Issued January 2012 - September 2012 [Member]	'	'
Short-term Debt [Line Items]	'	'
Interest rate of notes payable	7.00%	7.00%

Contingent_Royalty_Liability_A

Contingent Royalty Liability - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012
Contingent Royalty Liability [Line Items]	'	'	'
Convertible promissory notes	'	'	$16,000,000
Cash consideration in exchange of agreement	25,000	'	'
Royalty percentage diverted to Royalty Realization IV, description	'Company agreed to instruct Navidea to pay the 8% royalty due to the Company directly to Royalty Realization IV if and when such royalty is earned by the Company	'	'
Long-term contingent liability	$0	$16,000,000	'
Maximum [Member]	'	'	'
Contingent Royalty Liability [Line Items]	'	'	'
General partner equity ownership percentage	10.00%	'	'
Royalty Realization IV, LLC Royalty Agreement [Member]	'	'	'
Contingent Royalty Liability [Line Items]	'	'	'
Percentage of royalties on future sale	8.00%	'	'
Percentage of royalty payment to Royalty Realization IV	8.00%	'	'

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012
Deferred Revenue Disclosure [Abstract]	'	'	'
Amount of non-refundable option fee	$500,000	'	'
Sublicense execution payment	'	'	175,000
Navidea common stock value	306,357	306,357	1,146,000
Navidea common stock, shares	1,150,000	'	300,000
Patent expiration date	30-Jun-30	'	'
Unearned revenue recorded as current liability	73,731	73,730	'
Unearned revenue recorded as long-term liability	1,142,816	1,216,547	'
Contingent milestone payments	2,900,000	'	'
Milestone payments	$2,500,000	'	'
Issuance of additional common stock	550,000	'	'
Issuance of additional shares when certain cumulative net sales of the approved product are achieved	400,000	'	'
Royalties based on net sales, Lower range	10.00%	'	'
Royalties based on net sales, Upper range	14.00%	'	'
Obligation to pay milestone payments to Harvard, percentage	5.00%	'	'
Obligation to pay royalties to Harvard, percentage	2.00%	'	'

Stockholders_Deficit_Additiona

Stockholders' Deficit - Additional Information (Detail) (USD $)

12 Months Ended

254 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 27, 2012

Jun. 01, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2009

Dec. 31, 2009

Dec. 31, 2013

Jun. 01, 2011

OptionPlans

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series F Preferred Stock [Member]

Arthur Koenig [Member]

Ingalls and Snyder Value Partners, LP [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Robert Gipson [Member]

Series A Preferred Stock [Member]

Series D Preferred Stock [Member]

Series E Preferred Stock [Member]

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Robert Gipson [Member]

Series F Preferred Stock [Member]

Schedule Of Restricted Stock Granted [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchased total shares of common Stock

'

'

'

'

'

'

'

'

'

'

'

537,931

1,793,104

2,331,035

2,868,965

'

'

'

'

'

'

'

'

'

'

Total payment for repurchase of Common Stock

'

$1,866

'

$28,222

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing price per shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.08

'

'

'

'

'

'

'

'

'

Aggregate value of the shares reacquired

'

1,866

7,172

'

'

'

'

'

'

'

'

'

'

23,311

28,690

'

'

'

'

'

'

'

'

'

'

Convertible Preferred stock, shares designated

1,000,000

1,000,000

'

1,000,000

25,000

25,000

500,000

500,000

800

800

'

'

'

'

'

'

'

1,000,000

25,000

500,000

800

200,000

'

'

'

Series F convertible preferred stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

196,000

'

'

Proceeds from sale of convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,900,000

'

'

Conversion of Series F Preferred to common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,600,000

'

4,600,000

'

'

'

'

'

'

'

184,000

Series F Stock converted common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25

'

Cumulative accrued interest

'

'

'

640,874

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

640,874

'

Series F Stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000

'

Discount per share

'

'

'

'

'

'

'

'

'

'

$25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate computed for original Issue Price

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series F Stock net issuance cost

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Series F Stock value

20,942

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of company common stock

3,050,000

'

'

3,050,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual increase in the number of shares

400,000

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of outstanding common stock

4.00%

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based employee compensation expense

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of other stock option plan

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for grant

809,172

'

'

809,172

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserve

3,811,652

'

'

3,811,652

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Deficit_Summary_o

Stockholders' Deficit - Summary of Options Issued and Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Outstanding stock options at the beginning of year, Shares	3,010,980	'
Granted, Shares	0	0
Exercised, Shares	'	'
Forfeited and expired, Shares	-8,500	'
Outstanding and exercisable stock options at year end, Shares	3,002,480	3,010,980
Outstanding stock options at the beginning of year, Weighted Average Exercise Price	$1.51	'
Granted, Weighted Average Exercise Price	'	'
Exercised, Weighted Average Exercise Price	'	'
Forfeited and expired, Weighted Average Exercise Price	$5	'
Outstanding and exercisable stock options at year end, Weighted Average Exercise Price	$1.50	$1.51

Stockholders_Deficit_Summarize

Stockholders' Deficit - Summarizes Information about the Stock Options Outstanding and Exercisable (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Outstanding	3,002,480
Weighted Average Remaining Contractual Life	'9 months 18 days
Weighted Average Exercise Price	$1.50
Range of Exercise Prices from $1.15 to $1.36 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Minimum Range of Exercise Price	$1.15
Maximum Range of Exercise Price	$1.36
Number Outstanding	2,287,500
Weighted Average Remaining Contractual Life	'4 months 24 days
Weighted Average Exercise Price	$1.15
Range of Exercise Prices from $2.00 to $3.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Minimum Range of Exercise Price	$2
Maximum Range of Exercise Price	$3
Number Outstanding	539,980
Weighted Average Remaining Contractual Life	'1 year 8 months 12 days
Weighted Average Exercise Price	$2.33
Range of Exercise Prices from $3.10 to $4.65 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Minimum Range of Exercise Price	$3.10
Maximum Range of Exercise Price	$4.65
Number Outstanding	155,000
Weighted Average Remaining Contractual Life	'3 years 9 months 18 days
Weighted Average Exercise Price	$3.17
Range of Exercise Prices from $4.99 to $6.96 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Minimum Range of Exercise Price	$4.99
Maximum Range of Exercise Price	$6.96
Number Outstanding	20,000
Weighted Average Remaining Contractual Life	'3 months 18 days
Weighted Average Exercise Price	$5.68

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Asset Measured at Fair Value (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available for sale securities	$196,650	$838,309
Total assets	196,650	838,309
Contingent royalty	'	16,000,000
Total liabilities	'	16,000,000
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available for sale securities	196,650	838,309
Total assets	196,650	838,309
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available for sale securities	'	'
Total assets	'	'
Contingent royalty	'	'
Total liabilities	'	'
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent royalty	'	16,000,000
Total liabilities	'	$16,000,000

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
			Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]
			Level 1 [Member]	Level 1 [Member]	Level 1 [Member]
			NAVB Stock [Member]	NAVB Stock [Member]	FPMI Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Short-term investments shares	'	'	95,000	285,000	39,209
Debt conversion amount	$16,000,000	$16,000,000	'	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Examination [Line Items]	'	'	'
US federal tax rate	35.00%	'	'
Unrecognized tax benefits	$2,822,531	$2,822,531	$2,822,531
Income tax interest and penalties	0	'	'
Tax years open to examination	'Years ended December 31, 2010 through December 31, 2013	'	'
Adjustments to the federal tax returns	0	'	'
Federal [Member]	'	'	'
Income Tax Examination [Line Items]	'	'	'
Federal NOL carryforwards	61,516,000	'	'
Federal credit carryforward	1,578,000	'	'
State [Member]	'	'	'
Income Tax Examination [Line Items]	'	'	'
Federal NOL carryforwards	27,325,000	'	'
Federal credit carryforward	$1,110,000	'	'
Internal Revenue Service (IRS) [Member] | Minimum [Member]	'	'	'
Income Tax Examination [Line Items]	'	'	'
Tax years under audit	'2007	'	'
Internal Revenue Service (IRS) [Member] | Maximum [Member]	'	'	'
Income Tax Examination [Line Items]	'	'	'
Tax years under audit	'2008	'	'

Income_Taxes_Summary_of_Deferr

Income Taxes - Summary of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryforward	$22,952,000	$31,338,000
Capitalized research and development expenses	6,055,000	10,402,000
License fees	277,000	325,000
Stock-based compensation expense	2,264,000	2,264,000
Other	547,000	737,000
Gross deferred tax assets	32,095,000	45,066,000
Valuation allowance	-32,095,000	-45,066,000
Net deferred tax assets	'	'

Income_Taxes_Summary_of_Report

Income Taxes - Summary of Reported Tax Benefit and Amount Computed Using U.S. Federal Statutory Rate (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Tax provision (benefit) at statutory rate	($321,000)	($1,009,000)
State taxes, net of federal benefit	985,000	267,000
Expiring state net operating loss carryforward	'	455,000
Gain on forgiven interest and cancellation of debt and other	2,567,000	2,567,000
Decrease in valuation allowance	-6,731,000	-5,080,000
Permanent items	6,069,000	2,800,000
Income tax benefit	'	'

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Tax Benefit (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Examination [Line Items]	'	'
Gross tax assets	$32,095,000	$45,066,000
Valuation allowance	-32,095,000	-45,066,000
Net deferred tax assets	'	'
Net Operating Losses and Capitalized Research and Development Expenditures [Member]	'	'
Income Tax Examination [Line Items]	'	'
Gross tax assets	4,391,000	-3,382,000
Valuation allowance	-4,391,000	3,382,000
Net deferred tax assets	'	'
Net Operating Losses and Capitalized Research and Development Expenditures [Member] | Federal [Member]	'	'
Income Tax Examination [Line Items]	'	'
Gross tax assets	3,574,000	-2,737,000
Net Operating Losses and Capitalized Research and Development Expenditures [Member] | State [Member]	'	'
Income Tax Examination [Line Items]	'	'
Gross tax assets	$817,000	($645,000)

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning Balance	$2,822,531	$2,822,531
Additions based on tax positions related to the current year	'	'
Ending Balance	$2,822,531	$2,822,531

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2014

Feb. 01, 2013

2-May-12

Dec. 31, 2013

Jul. 27, 2013

Jul. 31, 2013

Dec. 31, 2013

Feb. 28, 2014

Dec. 31, 2013

sqft

Subsequent Event [Member]

Boston Children's Hospital and Children's Medical Center Corporation [Member]

Biostorage Technologies, Inc [Member]

Biostorage Technologies, Inc [Member]

Biostorage Technologies, Inc [Member]

Biostorage Technologies, Inc [Member]

Biostorage Technologies, Inc [Member]

Biostorage Technologies, Inc [Member]

BCH and CMCC [Member]

Installment

Installment One [Member]

Installment Two [Member]

Subsequent Event [Member]

Installment Three [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Area of office space

'

200

'

'

'

'

'

'

'

'

'

'

Total rent expense

'

$25,800

$71,500

'

'

'

'

'

'

'

'

'

Rent expenses

'

4,141,300

'

'

'

'

'

'

'

'

'

'

Rent expense in auburndale

'

500

'

'

'

'

'

'

'

'

'

'

Rent expenses

'

2,500

'

'

'

'

'

'

'

'

'

'

Amount claimed

'

'

'

'

642,906

119,363

'

'

'

'

'

-185,000

Shares received against execution of sublicense granted

'

'

'

'

'

'

'

'

'

'

'

20,000

Amount claimed

'

'

'

40,000

'

'

95,000

'

'

'

'

'

Number of share

'

20,000

'

'

'

'

'

'

'

'

'

'

Value of common stock

'

40,000

'

'

'

'

'

'

'

'

'

'

Agreement amount

'

'

'

'

'

'

'

75,000

10,000

40,000

25,000

'

Number of installments

'

'

'

'

'

'

3

'

'

'

'

'

Gain (loss) related to litigation settlement

'

'

'

'

'

'

20,000

'

'

'

'

'

Judgment vacated date

'

'

'

'

'

'

28-Feb-14

'

'

'

'

'

Notice days for breach remains uncured

'

'60 days

'

'

'

'

'

'

'

'

'

'

License agreements towards Harvard License Agreements

'

8,750

'

'

'

'

'

'

'

'

'

'

Sublicense execution payment

'

175,000

'

'

'

'

'

'

'

'

'

'

Period for cash payment to Harvard due, following the first commercial sale of Altropane product

'

'30 days

'

'

'

'

'

'

'

'

'

'

Stock received as part of the sublicense agreement

15,000

5,000

15,000

'

'

'

'

'

'

'

'

'

Company is obligated to transfer shares of the Navidea common stock received by the Company

'

5,000

'

'

'

'

'

'

'

'

'

'

Agreed Payment on option agreement

'

10,000

'

'

'

'

'

'

'

'

'

'

Payment on option agreement

'

$200,000

'

'

'

'

'

'

'

'

'

'

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (USD $)	12 Months Ended		254 Months Ended	16 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
				Robert Gipson [Member]
Related Party Transaction [Line Items]	'	'	'	'
Purchase of stock	$725,000	$510,000	$59,720,000	$500,000